Two pathways, one goal: stimulating GH secretion

In the research literature on the somatotropic axis, two major families of peptides are studied for their ability to stimulate the secretion of growth hormone (GH) by the pituitary gland — but they act through different receptors and mechanisms.

GHRH (Growth Hormone-Releasing Hormone)

GHRH analogs, such as tesamorelin, bind to the GHRH receptor on somatotropic cells of the pituitary gland. They reproduce the action of the natural physiological signal that triggers the synthesis and release of GH. This is a so-called "upstream" mechanism, which broadly respects the natural pulsatile secretion rhythm.

GHRP (Growth Hormone-Releasing Peptide)

GHRPs, such as ipamorelin, act on a different receptor: the ghrelin receptor (GHS-R). This mechanism also amplifies GH secretion, but through a pathway distinct from that of GHRH.

Why the literature often studies both together

Since the two families act on different receptors, research has looked into combining them: the hypothesis under study is that simultaneous activation of both pathways produces a stronger signal than each compound taken alone, with each acting on a distinct link in GH regulation.

Level of evidence The receptor mechanisms of both families are well characterized in the pharmacological literature. Data combining the two classes of compounds remain mostly preclinical and community-sourced, with fewer controlled trials specifically dedicated to the combination.

To learn more

See our Muscle Gain Stack, which combines Ipamorelin (GHRP) and Tesamorelin (GHRH), the two families discussed in this article.